Trial Profile
Evaluating the Benefit of Additional Platelet Inhibition in Acute Coronary Syndrome Patients With High Platelet Reactivity Undergoing PCI.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders; Thrombosis
- Focus Therapeutic Use
- Acronyms APACS-HPR
- 16 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 31 Oct 2013 Accrual to date is 23% according to United Kingdom Clinical Research Network.
- 13 Jun 2013 Accrual to date is 50% according to United Kingdom Clinical Research Network.